{"id":"9be01b83f691","type":"article","url":"https://hartvaat.nl/2025/07/09/coronaire-plaquefenotypeveranderingen-bij-lipidenverlagende-therapie-en-cardiova/","title":"Coronaire plaquefenotypeveranderingen bij lipidenverlagende therapie en cardiovasculaire events","title_en":"Modifications of coronary plaque phenotype on lipid-lowering therapies and risk of cardiovascular events: a systematic review and meta-regression analysis","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog"],"tags":["acuut-coronair-syndroom","atherosclerose","coronaire-ct-angiografie","dyslipidemie","ezetimibe","farmaco-economie","inflammatie","lipide-aferese","lipidenverlaging","lipoproteïne-a","niet-statine-therapie","obesitas","percutane-coronaire-interventie","plaquekarakterisatie","secundaire-preventie","select-trial","stabiel-coronairlijden","yellow-iii"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(25)01331-0/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(25)01331-0/fulltext","authors":["Giuseppe Patti","Leonardo Grisafi","Danila Azzolina","Luca Cumitini","Domenico D'Amario","Marco Mennuni"],"significance":5,"published":"2025-07-09","source_date":"2025-07-09","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/","https://hartvaat.nl/kennis/lipiden/pcsk9-remmers-evolocumab-alirocumab/"],"congress":"","summary_en":"This systematic review and meta-regression quantified the relationship between lipid-lowering therapy-induced coronary plaque phenotype changes on OCT and major adverse cardiovascular events. Plaque stabilisation correlated with reduced event rates across therapeutic classes.","created":"2026-07-03T10:25:44Z","updated":"2026-07-03T13:25:07Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"De relatie tussen coronaire plaquefenotypeveranderingen op OCT en de afname van ernstige cardiovasculaire events bij lipidenverlagende therapie was onbekend. Deze systematische review en meta-regressie kwantificeerden dit verband.","abstract_original":"The specific relationship between changes in coronary plaque phenotype by optical coherence tomography (OCT) and decrease in major adverse cardiovascular events (MACE) among patients receiving lipid-lowering therapies (LLTs) is unknown. Aim was to quantify the relationship between LLTs-related improvement of coronary plaque phenotype (e.g. coronary plaque stabilization, as assessed by OCT) and MACE occurrence."}